390 related articles for article (PubMed ID: 27462073)
21. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
22. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J
J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870
[TBL] [Abstract][Full Text] [Related]
23. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
24. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
25. Methods to study the structure of misfolded protein states in systemic amyloidosis.
Fändrich M; Schmidt M
Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
[TBL] [Abstract][Full Text] [Related]
26. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
27. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
28. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005.
Pradhan T; Sarkar R; Meighen-Berger KM; Feige MJ; Zacharias M; Reif B
Nat Commun; 2023 Jun; 14(1):3755. PubMed ID: 37353525
[TBL] [Abstract][Full Text] [Related]
30. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
31. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.
Monis GF; Schultz C; Ren R; Eberhard J; Costello C; Connors L; Skinner M; Trinkaus-Randall V
Am J Pathol; 2006 Dec; 169(6):1939-52. PubMed ID: 17148659
[TBL] [Abstract][Full Text] [Related]
32. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells.
Jordan TL; Maar K; Redhage KR; Misra P; Blancas-Mejia LM; Dick CJ; Wall JS; Williams A; Dietz AB; van Wijnen AJ; Lin Y; Ramirez-Alvarado M
Leukemia; 2020 May; 34(5):1383-1393. PubMed ID: 31796914
[TBL] [Abstract][Full Text] [Related]
33. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
34. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
35. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
36. The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity.
Iannuzzi C; Irace G; Sirangelo I
Molecules; 2015 Feb; 20(2):2510-28. PubMed ID: 25648594
[TBL] [Abstract][Full Text] [Related]
37. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.
DiCostanzo AC; Thompson JR; Peterson FC; Volkman BF; Ramirez-Alvarado M
J Biol Chem; 2012 Aug; 287(33):27997-8006. PubMed ID: 22740699
[TBL] [Abstract][Full Text] [Related]
39. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
40. Towards understanding the structure-function relationship of human amyloid disease.
Dealwis C; Wall J
Curr Drug Targets; 2004 Feb; 5(2):159-71. PubMed ID: 15011949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
